FEMY · Femasys Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $424.9K | - | $729.4K | $409.3K | $341.3K | - | $554.9K | $221.5K | $271.1K | - |
| Cost of Revenue | $158.6K | - | $293.8K | $158.2K | $117.3K | - | $190.8K | $73.1K | $88.5K | - |
| Gross Profit | $266.3K | - | $435.6K | $251.1K | $224.0K | - | $364.1K | $148.4K | $182.6K | - |
| R&D | $1.31M | - | $1.38M | $1.41M | $2.97M | - | $2.30M | $1.98M | $1.77M | - |
| SG&A | $1.78M | - | $1.48M | $1.62M | $1.72M | - | $1.53M | $1.61M | $1.50M | - |
| Total Operating Expenses | $4.49M | - | $4.09M | $4.10M | $5.68M | - | $5.48M | $4.63M | $3.65M | - |
| D&A | $82.3K | - | $85.7K | $86.3K | $84.9K | - | $76.3K | $67.6K | $71.2K | - |
| Operating Income | ($4.22M) | - | ($3.65M) | ($3.85M) | ($5.46M) | - | ($5.12M) | ($4.48M) | ($3.46M) | - |
| Interest Expense | $176.6K | - | $532.1K | $491.5K | $361.6K | - | $413.3K | $198 | $361.6K | - |
| Income Tax | $0 | - | $0 | $0 | $0 | - | $1.2K | $0 | - | - |
| Net Income | $846.1K | - | ($4.19M) | ($4.59M) | ($5.90M) | - | ($5.41M) | ($4.68M) | ($3.60M) | - |
| EPS - Basic | $0.00 | - | ($0.10) | ($0.16) | ($0.23) | - | ($0.24) | ($0.21) | ($0.17) | - |
| EPS - Diluted | $0.00 | - | ($0.10) | ($0.16) | ($0.23) | - | ($0.24) | ($0.21) | ($0.17) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.39M | $9.27M | $4.57M | $3.22M | $3.82M | $3.45M | $7.61M | $13.53M | $17.84M | $21.72M |
| Accounts Receivable | $172.3K | $616.6K | $572.2K | $254.6K | $233.6K | $488.4K | $378.3K | $92.5K | $120.5K | $98.9K |
| Inventory | $6.11M | $5.74M | $5.78M | $5.23M | $3.86M | $3.05M | $1.94M | $1.32M | $971.3K | $667.1K |
| Accounts Payable | $1.60M | $1.83M | $2.17M | $3.26M | $2.33M | $1.42M | $1.12M | $951.5K | $1.10M | $1.14M |
| Current Assets | $12.34M | $16.46M | $12.25M | $9.75M | $9.13M | $8.02M | $11.30M | $15.93M | $19.88M | $23.18M |
| Total Assets | $16.50M | $20.72M | $16.29M | $13.78M | $13.28M | $12.45M | $15.59M | $20.28M | $24.37M | $27.76M |
| Current Liabilities | $3.16M | $3.64M | $10.54M | $10.96M | $9.84M | $8.58M | $2.87M | $2.46M | $2.36M | $3.05M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $9.21M | $14.85M | $11.73M | $12.27M | $11.28M | $10.14M | $9.62M | $9.03M | $8.76M | $9.40M |
| Stockholders' Equity | $7.29M | $5.87M | $4.56M | $1.51M | $2.00M | $2.30M | $5.97M | $11.25M | $15.61M | $18.35M |
| Retained Earnings | ($144.98M) | ($145.83M) | ($141.88M) | ($137.68M) | ($133.10M) | ($127.20M) | ($122.07M) | ($116.67M) | ($111.98M) | ($108.38M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.14M) | - | - | - | ($4.77M) | - | - | - | ($4.57M) | - |
| Investing Cash Flow | ($79.1K) | - | - | - | ($96.6K) | - | - | - | ($90.2K) | - |
| Financing Cash Flow | $342.3K | - | - | - | $5.23M | - | - | - | $778.2K | - |
| CapEx | $79.1K | - | - | - | $96.6K | - | - | - | $64.6K | - |
| Free Cash Flow | ($4.22M) | - | - | - | ($4.86M) | - | - | - | ($4.63M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 62.7% | - | 59.7% | 61.4% | 65.6% | - | 65.6% | 67.0% | 67.3% | - |
| Operating margin | -994.0% | - | -500.9% | -941.1% | -1600.1% | - | -922.4% | -2023.7% | -1277.1% | - |
| EBITDA margin | -974.7% | - | -489.2% | -920.0% | -1575.2% | - | -908.6% | -1993.2% | -1250.8% | - |
| Net margin | 199.1% | - | -575.1% | -1120.5% | -1727.9% | - | -974.7% | -2115.1% | -1327.5% | - |
| Free cash flow margin | -993.8% | - | - | - | -1424.7% | - | - | - | -1708.6% | - |
| FCF / Net income | -4.99 | - | - | - | 0.82 | - | - | - | 1.29 | - |
| R&D / Revenue | 308.2% | - | 189.5% | 345.6% | 869.8% | - | 415.1% | 892.1% | 653.1% | - |
| SG&A / Revenue | 419.5% | - | 202.6% | 395.1% | 504.8% | - | 275.9% | 727.7% | 554.3% | - |
| Effective tax rate | 0.0% | - | - | - | - | - | - | - | - | - |
| Return on assets | 5.1% | - | -25.8% | -33.3% | -44.4% | - | -34.7% | -23.1% | -14.8% | - |
| Return on equity | 11.6% | - | -92.1% | -304.2% | -295.3% | - | -90.6% | -41.6% | -23.1% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.91 | 4.53 | 1.16 | 0.89 | 0.93 | 0.93 | 3.94 | 6.47 | 8.43 | 7.59 |
| Quick ratio | 1.98 | 2.95 | 0.61 | 0.41 | 0.54 | 0.58 | 3.26 | 5.93 | 8.02 | 7.37 |
| Cash ratio | 1.71 | 2.55 | 0.43 | 0.29 | 0.39 | 0.40 | 2.65 | 5.49 | 7.57 | 7.11 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -23.9x | - | -6.9x | -7.8x | -15.1x | - | -12.4x | -22637.1x | -9.6x | - |
| Equity multiplier | 2.26 | 3.53 | 3.58 | 9.14 | 6.65 | 5.40 | 2.61 | 1.80 | 1.56 | 1.51 |
| Liabilities / Assets | 0.56 | 0.72 | 0.72 | 0.89 | 0.85 | 0.81 | 0.62 | 0.45 | 0.36 | 0.34 |
| Efficiency | ||||||||||
| Asset turnover | 0.03 | - | 0.04 | 0.03 | 0.03 | - | 0.04 | 0.01 | 0.01 | - |
| Inventory turnover | 0.03 | - | 0.05 | 0.03 | 0.03 | - | 0.10 | 0.06 | 0.09 | - |
| Days sales outstanding | 148d | - | 286d | 227d | 250d | - | 249d | 152d | 162d | - |
| Days inventory outstanding | 14050d | - | 7185d | 12075d | 12021d | - | 3706d | 6567d | 4004d | - |
| Days payable outstanding | 3677d | - | 2700d | 7531d | 7258d | - | 2146d | 4749d | 4517d | - |
| Cash conversion cycle | 10521d | - | 4771d | 4771d | 5013d | - | 1809d | 1970d | -351d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 24.5% | - | 31.4% | 84.8% | 25.9% | - | 127.1% | -30.9% | -7.8% | - |
| Revenue CAGR (3y) | 13.1% | - | 28.0% | 10.5% | 2.0% | - | 21.0% | 6.5% | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 18.9% | - | 19.6% | 69.2% | 22.7% | - | 130.2% | -29.4% | -3.3% | - |
| Operating income growth (YoY) | 22.7% | - | 28.6% | 14.1% | -57.7% | - | -25.4% | -52.7% | -13.8% | - |
| Net income growth (YoY) | - | - | 22.4% | 2.1% | -63.8% | - | -35.3% | -61.9% | -22.2% | - |
| EPS growth (YoY) | - | - | 58.3% | 23.8% | -35.3% | - | 7.7% | 4.5% | 32.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 13.1% | - | - | - | -4.9% | - | - | - | -74.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 265.1% | 154.7% | -23.7% | -86.6% | -87.2% | -87.4% | -42.8% | -12.6% | 26.3% | 20.4% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$2.29M totalBusiness Segment$2.29M · 100.0%
Geographic
$2.29M totalUS$1.39M · 60.8%
Non Us$899.8K · 39.2%
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing FEMASYS INC against the 5 most active filers in the same SIC group.